Company: oNKo-Innate Pty Ltd
Job title: CSO
Prof. Huntington is the head of the Cancer Immunotherapy Laboratory in the Biomedicine Discovery Institute at Monash University, Australia. He is an international leader on natural killer (NK) cell biology with notably contributions to: regulatory mechanisms of IL-15 signalling in NK cells, identification of human and murine NK cell differentiation pathways, novel xenograft models to study human NK cell biology and identification of multiple checkpoint in NK cell activation and tumour immunity. Prof. Huntington leads a research program aimed at deciphering the regulatory networks that control NK cell development and homeostasis and a drug discovery program using cutting-edge in vivo screens for novel checkpoints in NK cell activation for targeting in cancer immunotherapy. Prof. Huntington is President of MIN (Melbourne Immunotherapy Network), serves as project director for several pharmaceutical industry collaborative programs and is a co-founder and chief scientific officer of oNKo-Innate Pty Ltd.
Targeting NK Cells at Different Stages of the Cancer Immunity Cycle: Checkpoints & Next Generation NK Cell Therapies 4:40 pm
• Discussing NK cells’ control of metastasis • Highlighting NK cells driving tumor inflammation • NK cells potentiating immune checkpoint blockade response • Emerging activation checkpoint in NK cells • Strategies to target tumor resident NK cellsRead more
day: Day One